Open AccessTherapeutic Efficacy of Novel Antimicrobial Peptide AA139-Nanomedicines in a Multidrug-Resistant Klebsiella pneumoniae Pneumonia-Septicemia Model in Rats
Author(s) -
Hessel van der Weide,
Unai Cossío,
Raquel Gracia,
Yvonne M. te Welscher,
Marian T. ten Kate,
Aart van der Meijden,
Marco Marradi,
Jeffrey A. S. Ritsema,
Denise M. C. Vermeulen-de Jongh,
Gert Storm,
Wil H. F. Goessens,
Iraida Loinaz,
Cornelus F. van Nostrum,
Jordi Llop,
John P. Hays,
Irma A. J. M. BakkerWoudenberg
Publication year - 2020
Publication title -
antimicrobial agents and chemotherapy
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.07
H-Index - 259
eISSN - 1070-6283
pISSN - 0066-4804
DOI - 10.1128/aac.00517-20
Subject(s) - antimicrobial , klebsiella pneumoniae , pneumonia , multiple drug resistance , antibiotics , antimicrobial peptides , microbiology and biotechnology , pseudomonas aeruginosa , klebsiella pneumonia , medicine , bacteria , biology , escherichia coli , biochemistry , genetics , gene
Antimicrobial peptides (AMPs) have seen limited clinical use as antimicrobial agents, largely due to issues relating to toxicity, short biological half-life, and lack of efficacy against Gram-negative bacteria. However, the development of novel AMP-nanomedicines, i.e., AMPs entrapped in nanoparticles, has the potential to ameliorate these clinical problems. The authors investigated two novel nanomedicines based on AA139, an AMP currently in development for the treatment of multidrug-resistant Gram-negative infections.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom